- ATMANIRBHAR BHARAT ROJGAR YOJANA
ATMANIRBHAR BHARAT ROJGAR YOJANA
Focus: GS II- Social Justice and Governance (Government schemes)
Why in News?
The Union Cabinet, chaired by the Prime Minister has given its approval for extending the terminal date for registration of beneficiaries for availing the benefit under Aatmanirbhar Bharat Rojgar Yojana (ABRY) till 31st March, 2022.
About the Atmanirbhar Bharat Rojgar Yojana (ABRY):
- It is aimed at incentivising the creation of new employment opportunities during the Covid-19 economic recovery phase.
- It will provide subsidy for provident fund contribution for adding new employees to establishments registered with the Employees’ Provident Fund Organisation (EPFO).
- Government will pay both 12% employees’ contribution and 12% employers’ contribution i.e. 24% of wages towards EPF in respect of new employees in establishments employing upto 1000 employees for two years.
- Government will pay only employees’ share of EPF contribution i.e. 12% of wages in respect of new employees in establishments employing more than 1000 employee for two years.
- The subsidy amount under the scheme will be credited upfront only in Aadhaar-seeded EPFO accounts (UAN) of new employees.
Eligibility Criteria for Establishments:
- Establishments registered with EPFO will be eligible for the benefits if they add new employees compared to the reference base of employees as in September 2020.
- Establishments, with up to 50 employees, would have to add a minimum of two new employees.
- The organisations, with more than 50 employees, would have to add at least five employees.
- Any new employee joining employment in EPFO registered establishments on monthly wages less than Rs. 15,000.
- Time Period: The scheme extended the terminal date for registration of beneficiaries for availing the benefit under Aatmanirbhar Bharat Rojgar Yojana (ABRY) till 31st March, 2022.
Why in News?
Utilising indigenous knowledge system shared by a farmer from Gujarat, a poly-herbal and cost-effective medicine has been developed to treat Mastitis, an infectious disease of dairy cattle.
- Mastitis is a common infectious disease, which affects farm productivity due to fall in milk quality, thus impacting income-generating activities.
- Treatment of infected animals with antibiotics poses a public health hazard.
- This medicine has reduced the use of antibiotics and helped in the cost-effective management of the disease.